Share This

Public company info - Antengene Corporation Limited , 06996.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Antengene Corporation Limited, 06996.HK - Company Profile
Chairman Jay Mei
Share Issued (share) 671,000,000
Par Currency U.S. Dollar
Par Value 1.0E-4
Industry Biotechnology
Corporate Profile Business Summary: The group is a clinical-stage Asia-Pacific (APAC) biopharmaceutical company focused on innovative oncology medicines. Performance for the year: The group’s loss and total comprehensive loss were RMB146.0 million, RMB323.8 million, RMB106.8 million and RMB537.7 million for the years ended December 31, 2018 and 2019 and the six months ended June 30, 2019 and 2020, respectively. Business Review The group distinguish ourselves through the group’s strong R&D capabilities and strategic approach to developing novel oncology therapies. the group’s vision is to treat patients beyond borders and transform their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies. The group is led by an experienced management team with a proven track record in developing and commercializing oncology drugs globally. the group’s founder and CEO, Jay Mei, M.D., Ph.D., was a clinical research and development executive at Celgene. At Celgene, Dr. Mei was one of the leading members in the clinical development of multiple blockbuster drugs that represent the most significant part of Celgene’s portfolio today, including REVLIMID®, which is among the best-selling oncology therapies worldwide, and was also involved in the clinical development of POMALYST®, also one of the best-selling oncology drugs worldwide, and IDHIFA®, a first-in-class drug for the treatment of acute myeloid leukemia. the group currently focus on hematology and oncology, the therapeutic areas in which the group’s management team has a strong track record and extensive experience, to bring innovative therapies to patients in the APAC region. The group employ a combinatory and complementary R&D strategy to maximize the potential of the group’s pipeline assets which are synergistic to each other. As an example of the group’s combinatory approach, The group is developing ATG-010 (selinexor), an XPO1 inhibitor, in combination with the group’s other pipeline assets. the group plan to evaluate ATG-010 (selinexor) in combination with ATG-008 (onatasertib, also known as CC-223), a dual mTORC1/mTORC2 inhibitor in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in China (the MATCH trial) after the completion of the SEARCH trial, a Phase II clinical trial to investigate the safety and efficacy of ATG-010 (selinexor) as a single agent in patients with R/R DLBCL. the group believe such combination trial will bring synergistic clinical benefits, given ATG-008 (onatasertib) has demonstrated preliminary clinical activities in patients with DLBCL in a study conducted by Celgene. As an illustration of the group’s complementary approach, The group is strategically expanding the group’s clinical development of selective inhibitor of nuclear export (SINE) assets to new indications that are complementary to those being developed by the group’s partner. The group is developing ATG-010 (selinexor) for the treatment of high prevalence cancer types in the APAC region with significant unmet medical needs, including T-cell lymphoma and KRAS-mutant non-small cell lung cancer (NSCLC). The implementation of the group’s combinatory and complementary R&D approach is empowered by the group’s company-wide cross-functional collaboration and distributed drug development model. the group believe the group’s company-wide cross-functional collaboration enables us to identify and mitigate inherent risks early in the development process of the group’s innovative therapies. By utilizing a distributed drug development model, the group select the most suitable industry partners, including leading CROs, CDMOs and innovative drug discovery companies, and closely work with them to efficiently and effectively achieve the group’s drug development goals. Guided by the group’s differentiated drug discovery and development strategy, the group successfully identified the potential of the therapeutic SINE compounds. the group obtained an exclusive license from Karyopharm, a NASDAQ-listed commercial-stage pharmaceutical company, to develop and commercialize three SINE compounds (ATG-010 (selinexor), ATG-016 (eltanexor) and ATG-527 (verdinexor)) in the APAC region. ATG-010 (selinexor) is a first-in-class and only-in-class SINE compound targeting XPO1, a key nuclear export protein. It is the first and only SINE compound approved by the FDA. ATG-010 (selinexor) is granted conditional accelerated approval for use in the treatment of two hematological malignancies, namely multiple myeloma (MM) and DLBCL and is the only single-agent, orally-available therapy approved for the treatment of patients with R/R DLBCL. These approvals by the FDA, and the demonstrated potential of SINE compounds as backbone therapies in completed and ongoing trials validate the group’s visionary selection of XPO1 as a druggable target and the group’s SINE compounds as a novel class of drugs with wide anti-cancer potential. By efficiently utilizing the group’s resources, forming partnerships with other pharmaceutical and biotech companies and leveraging the group’s outstanding capability in target selection and differentiated discovery and development strategy, the group have established an innovative pipeline of 12 clinical and pre-clinical assets as of the Latest Practicable Date. Both of the group’s two Core Products have a promising post-proof-of-concept clinical and commercial profile, ATG-010 (selinexor) being first-in-class and only-in-class and ATG-008 (onatasertib) being potentially first-in-class. Among the group’s clinical stage assets, the group also have two other drug candidates in the validated SINE class, namely ATG-016 (eltanexor) and ATG-527 (verdinexor), which feature differentiated profiles that allow us to target a wide range of indications through both monoand combination therapies. ATG-019 (KPT-9274) is a potentially first-in-class orally available dual PAK4/NAMPT inhibitor for the treatment of non-Hodgkin lymphoma (NHL) and advanced solid tumors. ATG-017 (AZD0364) is a potent and selective ERK1/2 inhibitor with best-in-class potential for the treatment of various hematological malignancies and solid tumors driven by the aberrant RAS/MAPK pathway. The group aim to become a premier global biotech company with an end-to-end fully integrated platform from discovery to commercialization. To achieve this, the group plan to continue to implement the group’s multi-source innovation strategy, deepen cross-functional collaboration, apply the group’s distributed drug development model and enhance the group’s manufacturing and commercialization capabilities. the group will continue to actively expand across the APAC region through clinical development, registration and commercialization of ATG-010 (selinexor) and other assets in countries such as China, Australia and South Korea. The group is planning to further expand the group’s clinical development footprint to the U.S. in anticipation that multiple pre-clinical assets will enter into IND stage in the U.S. by 2021. Prospects: • Advance the development and commercialization of ATG-010 (selinexor) in China and other APAC markets • Advance the development of the group’s SINE portfolio and other pipeline assets • Continue to execute the group’s multi-source model to build a broad and deep innovative portfolio • Continue to develop manufacturing and commercialization capabilities • Further strengthen a pan-APAC biotech franchise and expand the group’s global presence

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.